Biopharmaceutical company AstraZeneca is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland.
COVID-19 Vaccine AstraZeneca (previously AZD1222) no longer in review procedure
AstraZeneca AG announced today that it is no longer pursuing marketing authorisation for its COVID-19 vaccine in Switzerland. The company has withdrawn its application for authorisation for its COVID-19 vaccine, which it submitted to Swissmedic in October 2020.
This means that there are currently no new authorisation applications pending for COVID-19 vaccines in Switzerland. The two mRNA vaccines Comirnaty® (Pfizer/BioNTech) and Spikevax® (Moderna) and the vector vaccine COVID-19 Vaccine Janssen currently have temporary authorisation in Switzerland.